Skip to main content
. 2021 Jan 20;206(5):999–1012. doi: 10.4049/jimmunol.2001082

FIGURE 2.

FIGURE 2.

Vaccine-elicited mAbs efficiently neutralize heterologous clade B pseudoviruses. (A) Abs cloned from macaque 25257 single IgG+ B cells collected 4 wk post–final immunization (week 24) were screened for neutralization against autologous F8 and heterologous tier 1A SF162 pseudoviruses using the standard TZM-bl reporter assay. The proportion of mAbs showing neutralization activity with IC50s ≤50 μg/ml against either virus is shown. (B) Heat map of IC50 values of mAbs tested against a panel of 13 pseudoviruses in the TZM-bl assay. Broadly neutralizing mAb VRC01 is shown as an intraassay reference control. All neutralization assays were performed with serial dilutions in duplicate and select mAbs were repeated twice to ensure accuracy. Cloned mAbs O.21–O.58 showed no activity against autologous F8 or heterologous SF162 or JRCSF and were not further tested. (C) Percentage breadth and (D) median IC50 value against all detected susceptible viruses shown in (B).